findmyKOL

Martin Tallman, MD

Enriched profile

Director of Faculty Mentorship and Career Development, Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Professor of Medicine, Northwestern University Feinberg School of Medicine · Northwestern University Feinberg School of Medicine

ORCIDNPI
RegionChicago, IL · MidwestSpecialtyHematologyFocusAcute Myeloid Leukemia Research+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceverified 2026Payments2021–2022NIH funding1993–2001

Martin Tallman is Director of Faculty Mentorship and Career Development, Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Professor of Medicine, Northwestern University Feinberg School of Medicine at Northwestern University Feinberg School of Medicine. OpenAlex indexes 1,299 publications with 89,799 citations (h-index 134); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Martin S. Tallman is Director of Faculty Mentorship and Career Development, Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern University Feinberg School of Medicine / Robert H. Lurie Comprehensive Cancer Center of Northwestern University. The public record shows 1,299 publications with 89,799 citations (h-index 134), centered on Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, Retinoids in leukemia and cellular processes. It also documents an investigator role on 9 registered clinical trials, 2 NIH-funded awards (1993–2001).

  • Most recent indexed publication: 2025 · Leukemia & lymphoma
  • Top research focus: Acute Myeloid Leukemia Research
  • 9 registered trials on ClinicalTrials.gov

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Leukemia (AML/ALL/CML/CLL)8 trialsMDS / MPN4 trialsLeukemia, Myeloid, Acute3 trialsMyeloproliferative Disorders2 trialsMultiple Myeloma1 trialPrecursor Cell Lymphoblastic Leukemia-Lymphoma1 trialLymphoma1 trialAnemia, Refractory, with Excess of Blasts1 trialLeukemia, Promyelocytic, Acute1 trialAnemia, Refractory1 trialLeukemia, Hairy Cell1 trial

Research focus

OpenAlex concept fingerprint
Acute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia researchRetinoids in leukemia and cellular processesChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Drugs & molecules

across trials, industry payments and publications
Arsenic trioxideClinical trials2Industry paymentsPublications1Tibsovogeneric · IvosidenibClinical trialsIndustry payments2Publications1BusulfanClinical trials3Industry paymentsPublications

Works with

trial sponsors and companies reporting payments
Northwestern UniversityClinical trials5Industry paymentsServier Pharmaceuticals LLCClinical trialsIndustry payments2AbbVie Inc.Clinical trialsIndustry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,299publications

Distinct works indexed by OpenAlex, matched via ORCID; 1 in PubMed.

89,799citations

Total citations across indexed works.

134h-index

Hirsch index (OpenAlex). i10-index 603.

Clinical & industry

trials, payments and federal funding
9clinical trials

Investigator role on registered studies.

View trials
5companies · 2021–2022

Companies reporting payments to CMS. Facts, not judgments.

View payments
2NIH grants · 1993–2001

Federally funded research awards.

View funding

Public positions

sourced statements on record
1 more sourced public position behind the reveal.Reveal →

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

5 companies reported payments to CMS in program years 2021–2022. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    48.5%
    CD38-directed Cytolytic Antibody23.3%
    Daratumumab100%
    Part B, office-administered18 patients
    PD-1 inhibitor15.4%
    Pembrolizumab100%
    Part B, office-administered11 patients
  • Metabolism & gastrointestinal

    21%
    Other antiemetics18%
    Fosaprepitant100%
    Part B, office-administered18 patients
    Serotonin-3 Receptor Antagonist3%
    Palonosetron hcl66%Granisetron hydrochloride34%
    Part B, office-administered31 patients
  • Anti-infectives

    15.6%
    Human Immunoglobulin G15.6%
    Immune globulin100%
    Part B, office-administered28 patients
4 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)0.7% facility · 99.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

2 NIH research awards on record, funded 19932001 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/martin-tallman-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/tallman-martin-bb562916

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • ResearchGate

    researchgate.net/profile/Martin-Tallman

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net
2 more verified accounts behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • Other

    ashpublications.org/ashclinicalnews/news/2457/Pulling-Back-the-Curtain-Martin-S-Tallman-MD

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ashpublications.org
  • Apple Podcasts

    podcasts.apple.com/us/podcast/covid-19-update-2-updates-from-new-york-city-drs-stephanie/id1017410619

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com
  • Other

    cancer.northwestern.edu/news/2022/tallman.html

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.northwestern.edu
4 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Inaugural clinician member

    Moleculin Biotech Annamycin Scientific Advisory Board

    2024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prnewswire.com
  • Director of Faculty Mentorship and Career Development

    Robert H. Lurie Comprehensive Cancer Center

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.northwestern.edu
  • Former Chief

    Leukemia Service, Memorial Sloan Kettering Cancer Center; Professor of Medicine, Weill Cornell Medical College

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org
1 more role behind the reveal.Reveal →

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.